Rechallenge with BRAF and MEK inhibitors in the treatment of metastatic melanoma: A case report with a mini-review
Open Access
- 30 July 2025
- journal article
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 74-82
Abstract
The management of patients with metastatic melanoma remains a difficult clinical problem. Real-world practice of treating patients with encorafenib and binimetinib after progression on combination immunotherapy and combination targeted therapy demonstrates good tolerability and achievements in disease control, including the central nervous system. After progression on chemotherapy, combination targeted therapy, and combination immunotherapy, the patient developed extensive brain and spinal cord lesions and suffered from neurological symptoms (headache, neck pain, back pain, seizures). Rechallenge with BRAFi+MEKi inhibitors and switching to new generation drugs allowed us to achieve disease control, regression of neurological symptoms and a good quality of life for more than 12 months. This clinical case demonstrates the potential efficacy of rechallenge with combination targeted therapy and switching to newer class drugs, which helps achieve a long-term disease control and improve the patient’s quality of life. The article also provides a discussion of possible management strategies for patients who have progressed on currently available BRAFi + MEKi inhibitors.Keywords
This publication has 24 references indexed in Scilit:
- BRAF/MEK inhibitor rechallenge in advanced melanoma patientsCancer, 2024
- Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trialNature Communications, 2024
- A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitorsMelanoma Research, 2022
- Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf -mutated melanomaOncoImmunology, 2021
- Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with OsimertinibTargeted Oncology, 2019
- Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanomaActa Pharmacologica Sinica, 2018
- Corrigendum to “Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*” [Eur J Cancer 91 (2018) 116–124]European Journal of Cancer, 2018
- Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trialThe Lancet Oncology, 2017
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialThe Lancet Oncology, 2012
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialThe Lancet, 2012